Syndax Pharmaceuticals, Inc. (the “Company” or “Syndax”) is a clinical stage biopharmaceutical company developing an innovative pipeline in areas of unmet need related to cancer. The Company's two lead product candidates are, SNDX-5613 and SNDX-6352, or axatilimab. SNDX-5613 is currently being conducted in the ongoing AUGMENT-101 Phase I trial, which is focused on targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1) protein for the treatment of MLL-rearranged (MLLr) acute leukemias and nucleophosmin 1 (NPM1) mutant AML.